JP2006160672A - Allergy inhibitor, food, allergy-inhibiting method using the same, immunosuppressed animal and method for making the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an IgE antibody inhibitor which inhibits the production of IgE in a living body, can prevent and improve the crisis of allergic diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis, and can safely and easily be taken, and to provide a food raw material, and the like. <P>SOLUTION: This allergy inhibitor is characterized by containing polysaccharide fine particles. The polysaccharide fine particles are preferably chitosan or xanthan gum having an average particle diameter of ≤50 μm. The form of the allergy inhibitor includes powder, capsules, tablets and granules. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to the provision of an allergy inhibitor and food material that can be expected to suppress IgE antibodies, in particular, prevent the onset of type I allergic diseases and anti-inflammatory. Furthermore, the present invention relates to an immunosuppressed animal to which the allergy inhibitor is administered and a method for producing the same.

  The morbidity rate and mortality rate of allergic diseases have been increasing worldwide over the past 10 years due to changes in diet and living environment. According to a private survey (present state and future prospects of new drug development, 1991 edition, Seed Planning Co., Ltd.), one in three people in Japan is typical of atopic dermatitis, bronchial asthma, allergic rhinitis, etc. It shows the symptoms of type I allergic disease, and this data is supported by the Ministry of Health and Welfare Health and Welfare Trend Survey (1991). Although allergic diseases are not directly related to life, they suddenly appear in the very young generation, and natural healing at an early stage cannot be expected. It is thought that it has a great influence on social activities.

  Type I allergic diseases are sensitized and developed by inhaling antigens such as house dust, mites, pollens, and fungi, and the following mechanism is considered. Sensitization is established when IgE antibody released by B cells is mediated by CD4-positive T cells that produce Th2-type cytokines and through general immune responses, and binds to receptors on mast cells at its Fc portion. To do. When the re-entry antigen crosslinks the Fab part of IgE, chemical mediators such as histamine and leukotriene are released, and these substances act on tissue inflammation, increased vascular permeability, smooth muscle contraction, increased mucus secretion, etc. Causes a illness.

  The most effective way to treat allergic diseases is to avoid contact with antigens, but there are side effects such as antihistamines in patients who are sensitized with antigens that are free and present throughout the living environment The reality is that we have to rely on general solutions using symptomatic treatments. For this reason, unless you continue to drink or apply the drug, the onset will be repeated, and you will be burdened financially and physically, and if you stop using it, you may be worried about worsening symptoms due to rebound Have

  In addition, in patent document 1, what refine | purified glucomannan (dietary fiber content 90% or more) obtained from the konjac refined powder, and made the average particle diameter 100 micrometers or less by giving a grinding | pulverization process is the case of konjac refined powder. It has been disclosed that it has a significantly higher IgE antibody-inhibiting ability and has an allergy-inhibiting action.

JP 2003-55233 A

  In view of the prior art as described above, the present invention suppresses IgE production in the living body, prevents the development of allergic diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis, and is a safe and easy to take allergy It intends to provide an inhibitor and a food material.

The inventors of the present invention have refined glucomannan (dietary fiber content of 90% or more) obtained from konjac refined powder to give an average particle size of 100 μm or less by pulverization, compared with konjac refined powder. It has been found that it has a remarkably high IgE antibody inhibitory activity and has an allergic inhibitory effect (Japanese Patent Laid-Open No. 2003-55233). The inventors of the present invention have continued intensive studies on other IgE antibody inhibitors, and in the subsequent studies, as a result of extensive investigation of the effects of polysaccharides subjected to micronization treatment, similar results were obtained in chitosan and xanthan gum fine powders. It has been found that it has antiallergic action and anti-inflammatory action, and has completed the present invention.
In order to achieve the above object, the present invention comprises the following constitution.

(1) An allergy suppressor comprising a polysaccharide fine powder.
(2) The allergy inhibitor according to (1), wherein the polysaccharide fine powder is chitosan having an average particle size of 50 μm or less.
(3) The allergy inhibitor according to (1), wherein the polysaccharide fine powder is xanthan gum having an average particle size of 50 μm or less.
(4) The allergy suppressor according to any one of (1) to (3) above, which is in the form of powder, capsule preparation, tablet, or granule.

(5) An allergy-suppressing food comprising fine polysaccharide powder.
(6) The allergy-suppressing food according to (5), wherein the polysaccharide fine powder is chitosan having an average particle size of 50 μm or less.
(7) The allergy-suppressing food according to (5), wherein the polysaccharide fine powder is chitosan having an average particle size of 50 μm or less.
(8) The allergy-suppressing food according to any one of (5) to (7), which is in the form of powder, capsule preparation, tablet, or granule.

(9) A method for suppressing allergy comprising orally administering the allergy suppressor according to any one of (1) to (4).
(10) A method for suppressing allergy comprising orally administering the allergy-suppressing food according to any one of (5) to (8).

(11) An immunosuppressed animal, wherein the allergy suppressing agent according to any one of (1) to (4) is administered to the animal.
(12) A method for producing an immunosuppressed animal comprising the step of administering to the animal the allergy suppressing agent according to any one of (1) to (4).
(13) An immunosuppressed animal, wherein the allergy-suppressing food according to any one of (5) to (8) is administered to an animal.
(14) A method for producing an immunosuppressed animal, comprising a step of administering the allergy-suppressing food according to any one of (5) to (8) to an animal.

  According to the present invention, by continuously orally administering an allergy inhibitor containing a fine polysaccharide powder, high production of IgE antibodies in vivo can be suppressed and allergic diseases can be prevented.

The method for suppressing type I allergy according to the present invention is characterized by continuously orally administering chitosan or xanthan gum fine powder processed to an average particle size of 50 μm or less.
The polysaccharide raw materials used in the present invention, chitosan or xanthan gum, have been used for many years as food materials and food additives, respectively, are highly safe, and suppress excessive IgE antibody production through continuous use. And allergic diseases can be prevented.

  The present invention relates to a specific use of a polysaccharide powder that has been subjected to a refinement treatment. The polysaccharides used in the present invention are known per se, and their physicochemical properties and the like are described, for example, by Keisuke Tsuji and Bunpei Mori “Science of Dietary Fiber 1997” and edited by Naomichi Kunizaki and Sadao Sano. "Food polysaccharides-Knowledge of emulsification, thickening, and gelation, 2001".

  The polysaccharide fine powder used in the present invention is not only embodied as its own powder, capsule formulation or tableting formulation, but also in a form containing it in a food product, that is, as a form of an allergy-suppressing food product. Embodied. In addition, allergic inhibitors used in the present invention are immunomodulators (IgE antibody inhibitors) because allergic diseases cause inflammation due to a complicated balance of the immune system (excess IgE antibody production). Alternatively, it can be considered as an anti-inflammatory agent.

The intake of an IgE antibody inhibitor is usually effective at 1-50 g / 60 kg body weight / day orally.
For allergic diseases caused by excessive IgE antibody production, the IgE antibody inhibitor according to the present invention can also be used as an allergic disease preventing agent or allergic disease preventing agent.

  The allergy inhibitor of the present invention is a fine powder of chitosan or xanthan gum processed to an average particle size of 50 μm or less, but may contain an auxiliary component as long as the function as an inhibitor is not impaired.

  Any other auxiliary component that may be contained in the present invention can be used as long as it is harmless to the human body. Any form of the inhibitor of the present invention is conceivable, for example, powder itself, capsule preparations such as gelatin capsules, tablets and granules, and it goes without saying that they may be mixed in ordinary foods. .

  In order to obtain an allergy-suppressing food used in the present invention, a fine powder of chitosan or xanthan gum may be blended in the form of a food, for example, in a biscuit-like food, in a powder form. In this invention, the minimum density | concentration in the foodstuff which each effect expresses is 1 weight% or more normally as the amount of fine powder of a polysaccharide.

Hereinafter, the present invention will be described in more detail with reference to examples. In addition, this invention is not limited to the following Example.
Example 1 Observation of pathological changes in allergic disease model mice <Experimental method>
As test animals, NC / Nga mice [Matsuda H, et al; Int. Immunol 9, 461 (1997)] was used. NC / Nga mice purchased 4-week-old males from Japan SLC Co., Ltd. As the basic feed, breeding MF (solid feed) manufactured by Oriental Yeast Co., Ltd. was used. As the test feed, a solid feed obtained by adding 5% by weight of the refined polysaccharide powders 1 to 3 to the basic feed was used.

The following were used for the fine polysaccharide powders 1-3 added to each feed.
Test feed 1; Konjac glucomannan (average particle size: 17 μm)
Test feed 2; chitosan (average particle size: 10 μm)
Test feed 3; xanthan gum (average particle size: 46 μm)

  A group of 5 NC / Nga mice was used, and each test animal group was allowed to freely feed the basic feed and each test feed for 8 weeks. The state of skin lesions was visually observed every two weeks, and the symptoms were scored. Skin inflammation was scored for itching (pruritus behavior), bleeding / erythema, edema, abrasion, and dryness. The score was 0; asymptomatic, 1; mild, 2; moderate, 3; intensity, and skin inflammation was shown as the total value.

  For pruritus behavior, video shooting was performed for 30 minutes for each group at 12 weeks of age, and the number of times the mouse scratched the auricle, back, abdomen, and face with the hind legs was measured every 20 minutes.

<Experimental result>
FIG. 1 shows the results of scoring the skin inflammation in mice in Example 1 above. An appearance photograph of a skin lesion at 12 weeks of age is shown in FIG. In FIG. 2, A is a basic feed administration group, B is a test feed 1 administration group, C is a test feed 2 administration group, and D is a test feed 3 administration group. Moreover, the result of having evaluated the influence which acts on pruritus behavior of a mouse | mouth at 12 weeks of age is shown in FIG.

  In Example 1 above, in the basal diet administration group, hair loss and bleeding were observed in the head, neck and auricle from around the age of 9 weeks, and the dermatitis score significantly increased (see FIG. 1). However, in the test feed 2 particulate chitosan-administered group and the test feed 3 particulate xanthan gum administration group, as in the glucomannan group of the test feed 1, significant relaxation of those lesions was observed, and the score was significantly suppressed. As apparent from FIG. 3, scratching behavior induced by itch was frequently observed in the basic feed administration group at 12 weeks of age, but significant suppression was observed in the test polysaccharides 1 to 3 administration group. It was.

Example 2 Analysis of Serum Antibody Level and Acute Phase Protein Level <Experimental Method>
Blood was collected from each group of test animals used in Example 1 every two weeks, and the blood was centrifuged at 1800 rpm for 10 minutes to obtain serum. The total amount of IgE in the serum was analyzed by sandwich ELISA. Moreover, the total amount of IgG1 at 12 weeks of age was similarly analyzed by sandwich ELISA. Furthermore, the amount of serum amyloid A protein (SAA) at which the blood concentration was increased in the inflammatory state at 12 weeks of age was analyzed by a competitive ELISA method.

<Experimental result>
In Example 2 above, blood was collected from NC / Nga mice every two weeks, and the result of analyzing the total amount of IgE in the serum is shown in FIG. As is clear from FIG. 4, a marked increase in IgE was confirmed in the basal diet administration group up to 12 weeks of age. In the group administered with the finely divided chitosan and xanthan gum powder according to the present invention, a remarkably high IgE antibody suppressing ability was observed as in the group of test feed 1 administered with the fine particle glucomannan.

  FIG. 5 shows the results of analyzing the total IgG1 level in serum at 12 weeks of age. Moreover, the result of having analyzed the amount of SAA is shown in FIG.

  Compared with the basic feed administration group, in the group administered with fine chitosan and xanthan gum powder, it became clear that the total amount of IgG1 in the serum was decreased, as in the fine feed glucomannan administration group of test feed 1. It was. Moreover, as shown in FIG. 6, it became clear that the amount of SAA which is an inflammatory marker is remarkably suppressed in the group of microparticulate polysaccharides of test feeds 1 to 3.

In Example 1, it is a figure which shows the result of having evaluated the skin inflammation state of atopic dermatitis model mouse NC / Nga by scoring. In Example 1, it is an external appearance photograph which shows the dermatitis (skin lesion) symptom in 12-week-old of atopic dermatitis model mouse NC / Nga. In Example 1, it is a figure which shows the result of having investigated the pruritus action of the mouse | mouth in 12-week-old. In Example 2, it is a figure which shows the result of having analyzed the total amount of IgE in serum. In Example 2, it is a figure which shows the result of having analyzed the total IgGl amount in serum. In Example 2, it is a figure which shows the result of having analyzed the amount of serum amyloid A protein (SAA).

Claims (14)

  An allergy inhibitor characterized by containing a fine powder of polysaccharides.   The allergy inhibitor according to claim 1, wherein the polysaccharide fine powder is chitosan having an average particle diameter of 50 µm or less.   The allergy inhibitor according to claim 1, wherein the polysaccharide fine powder is xanthan gum having an average particle size of 50 µm or less.   The allergy inhibitor according to any one of claims 1 to 3, which is in the form of powder, capsule preparation, tablet, or granule.   An allergy-suppressing food comprising a fine polysaccharide powder.   6. The allergy-suppressing food according to claim 5, wherein the polysaccharide fine powder is chitosan having an average particle size of 50 μm or less.   6. The allergy-suppressing food according to claim 5, wherein the polysaccharide fine powder is chitosan having an average particle size of 50 μm or less.   The allergy-suppressing food according to any one of claims 5 to 7, which is in the form of powder, capsule preparation, tablet, or granule.   An allergy-suppressing method comprising orally administering the allergy-suppressing agent according to any one of claims 1 to 4.   An allergy-suppressing method comprising orally administering the allergy-suppressing food according to any one of claims 5 to 8.   An immunosuppressed animal, wherein the allergy suppressing agent according to any one of claims 1 to 4 is administered to the animal.   A method for producing an immunosuppressed animal comprising the step of administering the allergy inhibitor according to any one of claims 1 to 4 to an animal.   An immunosuppressed animal, wherein the allergy-suppressing food according to any one of claims 5 to 8 is administered to the animal.   A method for producing an immunosuppressed animal, comprising a step of administering the allergy-suppressing food according to any one of claims 5 to 8 to the animal.